Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
about
Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.Structure of the Plexin Ectodomain Bound by Semaphorin-Mimicking Antibodies.Fab-based bispecific antibody formats with robust biophysical properties and biological activityThe Mysterious Ways of ErbB2/HER2 TraffickingThe role of neratinib in HER2-driven breast cancer.Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
P2860
Q35168105-D0BBB835-E14E-478D-A5FC-0632709C930EQ36040189-06D5FFFA-BDBB-4281-8F2F-338992BC9709Q36213193-14B2CF08-429D-4034-A0C7-328BFB1595B5Q38237727-D66F1540-D747-4F64-819C-A2E79E7E5E8BQ38664492-0C30098A-E2CF-4622-AE6D-A3168FDEA72DQ41838529-A46EDDF8-76D1-48BE-B481-834F3778D711Q51028189-3D165F28-B45F-4409-B720-98CE4671E88F
P2860
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@ast
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@en
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@nl
type
label
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@ast
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@en
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@nl
prefLabel
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@ast
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@en
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@nl
P2093
P2860
P1433
P1476
Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
@en
P2093
Elizabeth Luis
Gabriele Schaefer
J Michael Elliott
Justin M Scheer
Richard Vandlen
Sock-Cheng Lewin-Koh
Wendy Sandoval
P2860
P304
P356
10.1371/JOURNAL.PONE.0051817
P407
P577
2012-12-20T00:00:00Z